Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 3/20 | 0.52 |
| ▸ | MMP1 | P03956 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | MMP14 | P50281 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 4/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19584939 | 0.90 | MMP9 (0.56) | FCER2MMP1MMP9MMP8MMP14 | |
| SCHEMBL8374049 | 0.88 | FCER2 (0.50) | FCER2MMP1MMP9MMP8MMP14 | |
| SCHEMBL596493 | 0.87 | MME (0.59) | MMP9MMP8MMP14LTA4H | |
| SCHEMBL15810860 | 0.87 | CTSS (0.61) | FCER2MMP1HPGDSPPARG | |
| SCHEMBL596491 | 0.87 | MME (0.59) | MMP9MMP8MMP14LTA4H | |
| SCHEMBL15810862 | 0.87 | CTSS (0.61) | FCER2MMP1HPGDSPPARG | |
| SCHEMBL6248471 | 0.87 | CTSS (0.61) | FCER2MMP1HPGDSPPARG | |
| SCHEMBL3105957 | 0.84 | CA12 (0.55) | FCER2MMP1MMP9MMP8MMP14 | |
| SCHEMBL3103333 | 0.84 | LTA4H (0.56) | FCER2MMP1MMP9MMP8MMP14 | |
| SCHEMBL9109075 | 0.83 | HPGDS (0.56) | FCER2MMP1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732605-B2 | Synthesis of diketopiperazines | NEREUS PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732605-B2 | Synthesis of diketopiperazines | NEREUS PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732605-B2 | Synthesis of diketopiperazines | NEREUS PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060235226-A1 | Synthesis of diketopiperazines | BEYONDSPRING PHARMACEUTICALS, INC. | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235226-A1 | Synthesis of diketopiperazines | DHPS, COASY, TKT | FCER2 4479/4885MMP1 4274/4885MMP9 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.